In HERA, patients with HER2+ early invasive breast cancer who underwent surgery (with or without radiotherapy) plus adjuvant and/or neoadjuvant chemotherapy and had node-positive disease or node-negative disease with tumours > 1 cm were randomized to adjuvant trastuzumab for 1 year, 2 years, or observation [24]. This evidence concerns the gene ERBB2 and neoplasm.